Equities

InspireMD Inc

InspireMD Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.39
  • Today's Change-0.07 / -2.85%
  • Shares traded17.26k
  • 1 Year change-24.04%
  • Beta0.9340
Data delayed at least 15 minutes, as of Nov 12 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

  • Revenue in USD (TTM)6.57m
  • Net income in USD-25.52m
  • Incorporated2008
  • Employees65.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Milestone Scientific Inc8.42m-4.62m54.10m17.00--6.79--6.42-0.0614-0.06140.10960.1030.72740.576314.32495,440.60-40.16-55.48-56.48-74.7272.4463.97-55.21-88.941.81--0.0007--11.600.423320.41---7.99--
Rapid Micro Biosystems Inc26.17m-48.40m54.65m193.00--0.646--2.09-1.11-1.110.60281.970.20451.326.78135,595.90-37.81---43.12---4.82---184.93--4.19------31.44--13.71------
iCAD Inc18.80m-4.54m56.00m67.00--1.80--2.98-0.1735-0.0880.71851.170.44881.063.14280,537.30-10.84-23.94-13.90-34.1486.0476.96-24.16-45.024.13--0.00---12.54-7.5329.32--23.88--
Lucid Diagnostics Inc3.80m-54.15m56.69m70.00------14.92-1.23-1.230.08570.32380.0992--38.9754,285.71-121.82---274.96---67.39---1,227.76--1.71--0.4178--544.03--6.24------
Singular Genomics Systems Inc2.72m-91.89m57.10m255.00--0.414--20.98-37.37-37.371.1155.270.01080.286711.5310,674.51-36.46---38.85---41.11---3,375.72--8.04--0.0696--280.52---4.34------
Pheton Holdings Ltd628.59k-241.22k57.43m11.00--157.90--91.36-0.0201-0.02010.05240.0255------57,144.55--------74.90---38.37--0.3984--0.00---7.53---387.24------
Medinotec Inc8.38m-21.86k58.67m35.00----755.657.00-0.0019-0.00190.71460.21561.645.0217.62239,561.70-0.4275---0.5122--42.89---0.2607--2.326.610.3165--402.25---14.73------
Alpha Pro Tech, Ltd.59.29m4.14m58.73m124.0014.570.942411.480.99070.36640.36645.245.670.85961.689.07478,121.006.0115.216.2216.0639.5540.236.9912.9311.21--0.000.00-1.215.6027.642.935.50--
Apyx Medical Corp49.03m-28.37m60.06m252.00--3.48--1.22-0.8188-0.81881.420.42570.76721.823.96194,567.50-44.55-25.24-58.21-29.9761.9066.11-58.08-46.004.45-7.790.693--17.6125.8219.28--7.99--
IR-Med Inc0.00-3.47m60.48m6.00--166.52-----0.0499-0.04990.000.00510.00----0.00-197.95---273.36--------------0.3019-------3.70------
InspireMD Inc6.57m-25.52m63.11m65.00--1.32--9.61-0.7389-0.73890.19071.860.12022.574.73101,030.80-46.71-60.59-52.36-72.9723.8520.46-388.67-334.787.13--0.00--20.0011.50-7.71--41.57--
Heartbeam Inc0.00-16.91m64.26m15.00--7.35-----0.6375-0.63750.000.32780.00----0.00-106.50---113.62--------------0.00-------12.94------
Hyperfine Inc11.94m-41.45m65.51m131.00--0.9754--5.49-0.5773-0.57730.16630.92480.12620.98562.5691,160.30-43.81---48.08--44.51---347.05--7.24--0.00--61.90--39.54------
Vicarious Surgical Inc0.00-61.02m65.75m131.00--0.9124-----10.77-10.770.0012.220.00----0.00-61.68---66.62--------------0.00-------1,478.15------
Vivani Medical Inc0.00-24.20m69.62m44.00--2.92-----0.4643-0.46430.000.43160.00----0.00-44.89-56.58-50.97-67.66-------2,868.72----0.00-------84.69--40.33--
Xtant Medical Holdings Inc110.94m-3.33m71.96m207.00--1.50125.810.6487-0.0284-0.02840.84310.34541.381.406.35535,956.50-4.15-10.38-5.77-14.6861.6161.08-3.00-8.661.01-4.540.429--57.504.81107.78--18.47--
Data as of Nov 12 2024. Currency figures normalised to InspireMD Inc's reporting currency: US Dollar USD

Institutional shareholders

39.54%Per cent of shares held by top holders
HolderShares% Held
Rosalind Advisors, Inc.as of 30 Sep 20242.51m9.78%
Nantahala Capital Management LLCas of 30 Jun 20242.03m7.88%
Marshall Wace LLPas of 30 Jun 20241.86m7.24%
Soleus Capital Management LP (Investment Management)as of 30 Jun 20241.38m5.36%
Velan Capital Investment Management LPas of 30 Jun 2024904.03k3.52%
Pura Vida Investments LLCas of 30 Jun 2024450.52k1.75%
Millennium Management LLCas of 30 Jun 2024421.73k1.64%
Osiris Investment Partners LLCas of 05 Jun 2024336.03k1.31%
Affiance Financial LLCas of 30 Sep 2024183.75k0.72%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 202488.99k0.35%
More ▼
Data from 05 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.